𝔖 Bobbio Scriptorium
✦   LIBER   ✦

The lack of CNS effects of nizatidine, with and without alcohol, on psychomotor ability and cognitive function

✍ Scribed by I. Hindmarch; S. Gilburt

Publisher
John Wiley and Sons
Year
1990
Tongue
English
Weight
564 KB
Volume
5
Category
Article
ISSN
0885-6222

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

The aim of the study was to measure the effects of nizatidine (150 mg, 300 mg, and 600 mg), with and without alcohol (0.5 g/kg body weight) on a battery of test of psychomotor functioning, short‐term memory and subjective rating of sedation. A placebo and positive internal control (lorazepam 1 mg) crossover design was used, with each subject acting as her own control. The study population consisted of 10 healthy female volunteers with an age range of 20–50 years. The results show that nitatidine, at the range of doses studied, has no demonstrable effect on any of the measures of CNS activity and psychomotor performance. This lack of CNS effect was demonstrated in a study where the verum showed a consistent impairment of CNS activity. Furthermore there was no potentiation of the effects of alcohol by any of the doses of nizatidine used.

πŸ“œ SIMILAR VOLUMES

Effect of antidepressants on cognitive a
Effect of antidepressants on cognitive and psychomotor function: the lack of effect of reboxetine
✍ I. Hindmarch πŸ“‚ Article πŸ“… 1998 πŸ› John Wiley and Sons 🌐 English βš– 126 KB πŸ‘ 2 views

Treatments available for depression vary in their side-eects. Behavioural toxicity, the alteration of psychomotor performance and cognitive function, can be counter-therapeutic, especially in elderly patients or those already cognitively compromised by their illness. This double-blind, 10-way crosso

The effects of brofaromine alone and in
The effects of brofaromine alone and in conjunction with alcohol on cognitive function, psychomotor performance, mood and sleep in healthy volunteers
✍ J. S. Kerr; D. B. Fairweather; I. Hindmarch πŸ“‚ Article πŸ“… 1993 πŸ› John Wiley and Sons 🌐 English βš– 662 KB

## Abstract Brofaromine is a novel antidepressant that functions by the inhibition of the A form of monoamine oxidase (MAO). This inhibition is reversible, making brofaromine both pharmacologically and structurally different from most of the currently available MAO inhibitors. The drug has been sho

Three antidepressants (amitriptyline, do
Three antidepressants (amitriptyline, dothiepin, fluoxetine), with and without alcohol, compared with placebo on tests of psychomotor ability related to car driving
✍ Ian Hindmarch πŸ“‚ Article πŸ“… 1987 πŸ› John Wiley and Sons 🌐 English βš– 510 KB

Eight female volunteers received acute doses of amitriptyline 50 mg (AMI), dothiepin 50 mg (DOT), fluoxetine 40 mg (FLU) or placebo both with and without a 'social' dose of alcohol (ALC) equivalent to 0.5 g/kg body weight absolute alcohol. Performance on a variety of tests of psychomotor ability and

Evaluation of the efficacy of metaclazep
Evaluation of the efficacy of metaclazepam and its effects on sleep, psychomotor performance and cognitive function in anxious patients
✍ E. Ponciano; Z. Shamsi; A. F. Da Fonscca; D. B. Fairweather; I. Hindmarch πŸ“‚ Article πŸ“… 1998 πŸ› John Wiley and Sons 🌐 English βš– 137 KB πŸ‘ 2 views

The eects of single and multiple doses of metaclazepam were investigated in 60 anxious patients. A 15 mg nocturnal dose of metaclazepam was compared to two daily doses (5 mg in the morning and 10 mg at bedtime) in terms of ecacy and eects on various aspects of sleep, cognitive function and psychomot

The effects of acute and repeated doses
The effects of acute and repeated doses of moclobemide on psychomotor performance and cognitive function in healthy elderly volunteers
✍ J. S. Kerr; D. B. Fairweather; I. Hindmarch πŸ“‚ Article πŸ“… 1992 πŸ› John Wiley and Sons 🌐 English βš– 578 KB

The effects of moclobemide, a new selective and reversible MAO-A inhibitor, on cognitive function and psychomotor performance were measured in 12 healthy elderly male volunteers (with a mean age of 72.5 years). Subjects received moclobemide 200 mg, amitriptyline (positive internal control) 25 mg or